Wednesday, December 9, 2020 Daily Archives

Exploring Resin Modalities for Biotherapeutic Purification

by , , and

New chromatography supports must demonstrate improved selectivity, and bead technologies must be optimized for high binding capacity and product recovery. Drug manufacturers also need access to expertise and continued support from chromatography suppliers that can assist with method development and design of experiments (DoE) assessments. Working together, these industry groups can accelerate method development, increase process yield, reduce buffer consumption, minimize the number of unit operations, and improve overall process economies. Learn more in this Special Report about how resin…

December 9, 2020

MilliporeSigma accelerates $47m expansions on back of COVID surge

by

MilliporeSigma has expedited planned capacity expansions at sites in Massachusetts and New Hampshire after seeing a surge in demand for bioprocess equipment from coronavirus therapy and vaccine developers. The Jaffray, New Hampshire facility manufactures single-use components and filtration equipment for biopharma manufacturers. Having added 38,500 square feet of production space last year, MilliporeSigma is now moving forward with a $22 million 25,000 square-foot expansion, adding new production lines and equipment. Concurrently in Danvers, Massachusetts, a 65,000 square-foot expansion – representing…

December 9, 2020

Fareva enhancer: CureVac to use CDMO for COVID vaccine fill/finish

by

Messenger RNA (mRNA) vaccine developer CureVac has contracted CDMO Fareva for the fill and finish of COVID-19 vaccine candidate. Under terms of the deal – financials of which have not been disclosed – contract development and manufacturing organization (CDMO) Fareva will provide fill and finish capabilities for CureVac’s COVID-19 vaccine candidate, CVnCoV, from facilities in Val-de-Reuil and Pau, both in France. “We are proud to contribute to the fill and finish manufacturing of this innovative vaccine candidate from CureVac,†said…

December 9, 2020

Sinovac raises $500m to fund Coronavac trials and production

by

Sinovac Biotech has secured financing of $500m to fund further development of its candidate COVID-19 vaccine. The funding – which gives investor Sino Biopharma a 15% stake in the Beijing biotech – will be used to support clinical development of Coronavac, a vaccine that uses inactivated forms of COVID-19 to induce immune responses. Sinovac is conducting large-scale clinical trials of the vaccine in Brazil – the study was suspended in October before resuming last month – and Indonesia. In November…

December 9, 2020